FDA Approves Unknown Drug — NATCO

NATCO announced today that the FDA has approved Abbreviated New Drug Application (ANDA) 213267, dated April 27, 2023. This regulatory clearance is expected to reshape market dynamics for the drug by introducing a competitive, generic alternative to the current lineup. *(Note: The 'Substance' field was left blank in your request; please insert the specific drug name in the second sentence where indicated above.)*